Changing the UK COVID-19 vaccine dosing schedule

On December 31, 2020 the four UK Chief Medical Officers (CMOs) published a statement announcing changes to the dosing schedule for the second dose of the Pfizer/BioNTech and University of Oxford/AstraZeneca vaccines. It stated that the interval between the first and second dose should be extended from 3–4 weeks to up to 12 weeks. This rapid response examines the evidence behind this decision.

Changing the UK COVID-19 vaccine dosing schedule

The performance of COVID-19 vaccines in clinical trials and in real world conditions

COVID-19 vaccine roll-out started in the UK on 8 December 2020. Results from Phase 3 clinical trials have been published for all the vaccines approved for use in the UK. But how does the performance of vaccines under real world conditions differ from clinical trial results? When will we able to observe the impacts of the COVID-19 vaccination programme?

The performance of COVID-19 vaccines in clinical trials and in real world conditions
  • Rapid response

    Mass testing for COVID-19: January update on lateral flow tests

    The Government’s COVID-19 Winter Plan, relies on three things to provide the UK with a “route back to normality”: vaccines, treatments and testing. In addition to laboratory-based tests, lateral flow tests are being used for rapid testing in communities and workplaces. What are the latest data on how good these tests are? What are the pros and cons of using them for mass testing?

  • POSTnote

    AI and healthcare

    There are various applications of Artificial Intelligence (AI) in healthcare, such as helping clinicians to make decisions, monitoring patient health, and automating routine administrative tasks. This POSTnote gives an overview of these uses, and their potential impacts on the cost and quality of healthcare, and on the workforce. It summarises the challenges to wider adoption of AI in healthcare, including those relating to safety, privacy, data-sharing, trust, accountability and health inequalities. It also outlines some of the regulations relevant to AI, and how these may change. As healthcare is a devolved issue, policies on healthcare AI differ across the UK. This POSTnote focusses on regulations and policies relevant to England.

  • Rapid response

    Manufacturing COVID-19 vaccines

    The rapid production of safe, effective and consistent vaccines is essential for supporting COVID-19 immunisation programmes in the UK and globally. However, manufacturing vaccines is challenging for various reasons that include the complex processes involved, the specialist knowledge and experience required, and the natural variability of the biological materials and systems used. Urgent demand is leading to manufacturers and governments taking on significant financial risks in order to speed up production. What is the UK Government doing to accelerate vaccine manufacture? How are vaccines made? Why is manufacturing vaccines at large scales so challenging?

  • Rapid response

    COVID-19 and the digital divide

    The digital divide is the gap between people in society who have full access to digital technologies (such as the internet and computers) and those who do not. Concerns about the digital divide have been particularly acute during the COVID-19 pandemic as the internet and digital devices have played an important role in allowing people to access services, attend medical appointments and stay in touch with friends and family. What impact has the digital divide had on children and adults in the UK during the COVID-19 pandemic and what has been done to tackle it?

  • Resource

    COVID-19 glossary

    The most common scientific terms used in research that relates to COVID-19. This glossary will help you understand materials that describe the biology of Coronavirus and the spread of COVID-19. It can assist in the reading of research papers and help you understand language used in drug and vaccine development. It also has a comprehensive list of international and UK organisations involved in public health, their institutional acronyms and descriptions of their work.

  • Rapid response

    Monitoring wastewater for COVID-19

    Since early 2020, the UK has been carrying out wastewater monitoring for COVID-19. Wastewater samples are collected regularly across the country and analysed for SARS-CoV-2, the virus that causes COVID-19. Wastewater monitoring is part of monitoring systems to detect new COVID-19 outbreaks and support test and trace approaches. How can SARS-CoV-2 be detected in wastewater? How can wastewater monitoring be used as part of the response to the COVID-19 outbreak? And how are wastewater monitoring programmes being used across the UK and worldwide?

  • POSTnote

    Screen use and health in young people

    Devices with screens include game consoles, laptops and televisions. Screen use refers to activities undertaken on such devices and the time spent on them. Children’s screen use has increased over the past decade. Policy-makers and parents have expressed concerns about possible effects of screen use on children/young people’s development and health. This POSTnote provides an overview of how children/young people use screens, the opportunities and risks of this use, evidence on the possible effects on health and development, and evidence on ways to support healthy screen use.